**Background of CAPN6 Antibody**
CAPN6 (Calpain 6) belongs to the calpain family of calcium-dependent cysteine proteases, which regulate diverse cellular processes, including cytoskeletal remodeling, apoptosis, and signal transduction. Unlike most calpains, CAPN6 lacks critical catalytic residues, rendering it proteolytically inactive. It is thought to function as a regulatory molecule, potentially through interactions with other proteins or pathways. CAPN6 is highly expressed during embryonic development, particularly in the nervous system and skeletal muscle, suggesting roles in cell migration, differentiation, and tissue morphogenesis.
Aberrant CAPN6 expression has been linked to diseases such as cancers (e.g., sarcomas, neuroblastoma) and neurological disorders. Overexpression in tumors correlates with aggressive phenotypes, metastasis, and poor prognosis, implicating it as a potential therapeutic target. CAPN6 antibodies are essential tools for studying its expression, localization, and mechanistic roles. These antibodies enable techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding research into its physiological and pathological functions. Commercial CAPN6 antibodies are often validated for specificity using knock-down or knock-out models, ensuring reliability in experimental settings. Ongoing research aims to clarify CAPN6's unique regulatory mechanisms and therapeutic relevance in disease contexts.